CASE REPORT

A Metastatic Gastric Tumor from Ovarian Cancer

Mitsuhiro Kono¹, Yasuaki Nagami¹, Masaki Ominami¹, Taishi Sakai¹, Takeshi Fukuda²,
Shusei Fukunaga¹, Fumio Tanaka¹, Satoshi Sugimori¹, Hirokazu Yamagami¹,
Tetsuya Tanigawa¹, Masatsugu Shiba¹, Kazunari Tominaga¹, Toshio Watanabe¹,
Yasuhiro Fujiwara¹ and Tetsuo Arakawa¹

Abstract:
Gastric metastasis from ovarian cancer has rarely been reported. We herein report the case of a 64-year-old woman with gastric metastasis from ovarian cancer that was diagnosed as surgical stage IA. Diagnostic and staging laparotomy showed mucinous carcinoma of the right ovary. At one month after surgery, bone metastasis was detected via scintigraphy. On esophagastroduodenoscopy, a 10-mm elevated lesion with ulceration on the top was seen in the stomach. The immunohistochemical analysis of biopsy specimens showed that these metastases arose from ovarian cancer. We recommend that physicians remain aware of the possibility of gastric metastasis in patients with ovarian cancer.

Key words: gastric metastasis, ovarian cancer, mucinous carcinoma, biopsy

(Intern Med 57: 345-349, 2018)
(DOI: 10.2169/internalmedicine.9147-17)

Introduction

Although gastric metastases are uncommon, most arise from primary breast cancer, followed by melanoma and lung cancer (1). There have been few reports of gastric metastasis from ovarian cancer. This type of metastasis is extremely rare because malignant cells from the ovary usually spread through the intraperitoneal cavity (2). We herein report the first case of gastric metastasis from stage IA ovarian cancer.

Case Report

A 64-year-old woman with a history of hypertension, diabetes mellitus, and chronic renal failure (diabetic nephropathy stage V) was admitted to our hospital with bilateral ovarian tumors that had been diagnosed as mature cystic teratoma at a previous hospital. A physical examination identified anemia of the palpebral conjunctiva, with normal vital signs, leg edema, and tumor of 20 cm in size with tenderness in the lower abdomen. A laboratory examination revealed anemia, a low platelet count, and renal dysfunction (hemoglobin, 8.0 g/dL; platelets, 17,100/μL; creatinine, 5.39 mg/dL; estimated glomerular filtration rate, 6.88 mL/min). Her tumor marker levels were elevated, as follows: carbohydrate antigen 19-9 (CA 19-9), 175 U/mL; carcinoembryonic antigen (CEA), 197 U/mL; carbohydrate antigen 125 (CA 125), 9 U/mL; and sialyl Tn antigen (STn), 134 U/mL. Magnetic resonance imaging (MRI) revealed cystic masses of 13 cm and 6 cm in size on the right and left ovaries, respectively, with solid components that were suspected to be malignant tumors of the ovaries (Fig. 1a). No metastasis was observed on plain chest-to-pelvic computed tomography (CT) scans or pelvic MRI; however, enhanced CT could not be performed because of renal failure. Diagnostic and staging laparotomy was performed. An intraoperative rapid pathological diagnosis revealed mucinous carcinoma of the right ovary; thus, bilateral salpingo-oophorectomy, simple hysterectomy, pelvic and para-aortic lymph node dissection, and partial omental resection were performed. Right mucinous carcinoma without lymph node metastasis and left mature cystic teratoma were histologically diagnosed. The right ovarian capsule was not ruptured. There was no metastasis or vascular/lymphatic vessel invasion. The pT1aN0M0 mucin-
nous carcinoma (Union for International Cancer Control, 7th ed.) was diagnosed as surgical stage IA (International Federation of Gynecology and Obstetrics) ovarian cancer. Her tumor marker levels improved after surgery. At one month after surgery, the patient presented with back pain and re-elevated tumor marker levels (CA19-9, 86 U/mL; CEA, 832 U/mL; CA125, 446 U/mL; STn, 3,378 U/mL). Bone metastasis, which is atypical in ovarian cancer, was detected via scintigraphy (Fig. 1b). Esophagogastroduodenoscopy (EGD) was performed due to suspected metastasis from another primary cancer, and this revealed a 10-mm elevated lesion with ulceration at the top of the gastric fundus (Fig. 2b, c) that had not been observed 3 months earlier (Fig. 2a). CT showed no abnormal findings (including the pancreas and chest findings) and no tumors were observed in colonoscopy. Gastric and bone biopsies revealed mucinous carcinoma, and immunohistochemistry revealed that these metastases had arisen from ovarian cancer (Fig. 3). Despite the administration of additional chemotherapy, the patient died three months later.

**Discussion**

Metastatic disease involving the stomach is unusual. According to clinical and autopsy findings, the incidence of gastric metastasis is 0.2-0.7% (1). A review by Zhou and Miao found 17 cases (1.68%) of stomach metastasis among 1,010 patients with all types of malignant tumors (3). Another series of autopsies discovered 92 cases (1.28%) of gastric metastasis among 7,165 cases with all types of malignant tumors (4). Most gastric metastases arise from primary breast cancer, followed by melanoma and lung cancer (1).

Gastric metastasis from ovarian cancer is rare, but a few cases of gastric metastasis from ovarian cancer have been reported, because ovarian cancer typically spreads along the peritoneum and throughout the pelvic and abdominal cavities (1). The most frequent locations of occult metastatic disease from ovarian cancer are the omentum, the uterus and the fallopian tubes, the lymph nodes, the abdominal peritoneum, and the pelvic peritoneum (5). Because mucinous carcinoma is rare in ovarian cancer and the prognosis is poorer than that of serous carcinoma, gastric metastasis might not be reported (6). Although most metastatic sites are similar, regardless of the histological type, clear cell and mucinous carcinomas are associated with more frequent lymph node metastasis in comparison to serous carcinoma. Hematogenous metastasis is rare in each type. There have been no re-

---

**Figure 1.** a: Magnetic resonance imaging shows bilateral ovarian masses (red circle and yellow arrow). b: Bone scintigraphy reveals bilateral iliac and the uptake of the right sciatic nerve.

**Figure 2.** a: Esophagogastroduodenoscopy (EGD) before surgery shows no abnormality of the gastric fundus. b: EGD at one month after surgery shows an elevated lesion of 10 mm in size with ulceration at the top of the lesion in the posterior wall of the gastric fundus (yellow arrow). c: Chromoen- doscopy with indigo carmine shows a submucosal tumor with ulceration at the top.
ported cases of gastric metastasis from stage IA ovarian cancer. In malignant epithelial ovarian tumors, the tumor stage is determined by staging laparotomy. In the present case, the ovarian capsule of the cancer site did not demonstrate rupture to the peritoneum and abdominal cavity, and no distant metastasis was observed; thus, the cancer was diagnosed as surgical stage IA. However, it was undeniable that the small gastric metastatic lesion might have been detected by preoperative EGD with sufficient air insufflation, since bone metastasis was detected at one month after surgery. On the other hand, surgical intervention might have caused rapid hematogenous metastasis. Gastrointestinal involvement is usually limited to the seromuscular layer of the bowel and its mesentery. However, gastric metastasis also occurs via lymphatic channels or through the hematogenous route (1). Because the stomach receives a rich blood supply, it should be considered as a possible target organ of metastasis.

The clinical manifestations of metastasis to the stomach are nonspecific and include epigastric pain, melena, anemia, nausea, and vomiting (1). Because the most common gross appearance of gastric metastasis from ovarian cancer is a submucosal tumor (SMT) without mucosal involvement, most cases have no symptoms (4). Recently, ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) has been found to be useful in the detection of such occult gastric metastases (3). The interval between treatment of the primary tumor and diagnosis of metastatic tumor in the stomach is not specified, and ranges from 0 to 216 months, with a median of 24 months (Table). When tumor marker levels are elevated before and after surgery, such as in the present case, ¹⁸F-FDG PET/CT and upper gastrointestinal endoscopy should be recommended. Although the final diagnosis is easily obtained from endoscopic biopsies in over 90% of cases involving gastric metastasis from another site (1), there have only been 2 cases, including the present case, in which a diagnosis of gastric metastasis from ovarian cancer was made based on the examination of a biopsy specimen (Table). The main diagnostic method in previous cases has been surgical resection. Recently, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become the most popular diagnostic method, and surgery has successfully been avoided in 5 cases that were diagnosed by this method (Table). Because the present case had an SMT with ulceration, its diagnosis by means of biopsy might have been possible. The histological examination, showed that the origin of the tumor could be diagnosed with a combination of cytokeratin 7 (CK 7) and cytokeratin 20 (CK20). The positivity of the tumor cells for CK7 and CK20 reveals that the tumor was derived from mucinous carcinoma of the ovary (Fig. 3) (7). This is the first reported case of mucinous carcinoma; the most common histological type is serous carcinoma (12/14) (Table).

The treatment for metastasis is chemotherapy to the primary tumor. In the present case, we used paclitaxel-carboplatin combination therapy to treat the ovarian mucin...
Because the presence of gastric metastasis is likely to be a pre-terminal event, the prognosis is poor, and the survival period is extremely short (1).

The average survival period after the diagnosis of gastric metastasis is 15 months (Table). In addition, mucinous carcinoma demonstrates a low response to chemotherapy (12.5-26%). Additional treatment, such as adjuvant chemotherapy is not recommended for surgical stage IA epithelial tumors other than clear cell carcinoma. The 5-year survival rate of stage I ovarian cancer is 92%, whereas the rate of lymph node metastasis in stage IA cancer is reported to be 9.3% (8). We recommend that physicians keep in mind the possibility of gastric metastasis in patients with ovarian cancer, and periodically measure their tumor marker levels. In addition, 18F-FDG PET/CT and upper gastrointestinal endoscopy would be strongly recommended to detect gastric metastasis in patients whose tumor marker levels remain elevated after surgery, despite a diagnosis of stage IA ovarian cancer.

**Conclusion**

We herein reported a case of gastric metastasis from ovarian mucinous carcinoma, which was diagnosed by biopsy. We recommend that physicians remain aware of the possibility of gastric metastasis in patients with ovarian cancer.

The authors state that they have no Conflict of Interest (COI).

### References

1. Namikawa T, Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach. Surg Today **44**: 1392-1399, 2014.
2. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol **113**: 331-334, 2009.
3. Zhou JJ, Miao XY. Gastric metastasis from ovarian carcinoma: a case report and literature review. World J Gastroenterol **18**: 6341-6344, 2012.
4. Hwanqbo S, Kwon OK, Chung HY, Yu W. Improved survival of a patient with gastric and other multiple metastases from ovarian cancer by multimodal treatment: a case report. J Gastric Cancer **15**: 218-221, 2015.
5. Powless CA, Bakkum-Gamez JN, Aletti GD, Cliby WA. Randomized peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol **115**: 86-89, 2009.
6. Mizuno M, Kajiyama H, Shibata K, et al. Prognostic value of histological type in stage IV ovarian carcinoma: retrospective analysis of 223 patients. Br J Cancer **112**: 1376-1383, 2015.
7. Arlene E, Garcia S, Todd B, Shana NW, Thomas H, David SM. Is

### Table. A Review of the Reported Cases of Metastatic Gastric Tumors from Ovarian Cancer.

| Patient number | Reference | Age | Tumor location | Tumor size (cm) | Gross appearance | Histological type | Stage | Diagnosis | IPM (months) | Treatment | Outcome |
|---------------|-----------|-----|----------------|----------------|-----------------|-----------------|------|-----------|-------------|-----------|---------|
| 1             | 1         | 63  | L              | ND             | U               | Serous carcinoma | II   | EUS-FNA  | 72          | Surgery   | ND      |
| 1             | 2         | 42  | L              | 7              | SMT             | Serous carcinoma | IIC  | Laparoscopy | 216         | Chemotherapy | ND      |
| 3             | 3         | 55  | L              | 3.4x3, 7, 1.2x0.8 | SMT             | Papillary serous carcinoma | IIIB | EUS-FNA  | 24          | Chemotherapy | ND      |
| 4             | 4         | 62  | U              | 4              | Gastric ulcer   | Serous carcinoma | ND   | Surgery   | 15          | Surgery   | DOD at 6months |
| 5             | 5         | 62  | U              | 4              | Ulcerated SMT   | Poorly differentiated carcinoma | II   | EUS-FNA  | 84          | Surgery   | Alive at 1 year |
| 6             | 6         | 49  | L              | 2.5x2.5        | SMT             | Serous carcinoma | IIC  | EUS-FNA  | 52          | Chemotherapy | Alive at 18 months |
| 7             | 7         | 70  | M              | 3.8x4.8        | Ulcerated SMT   | Serous carcinoma | IV   | EUS-FNA  | 0           | ND        | ND      |
| 8             | 8         | 55  | L              | 4.5x4          | Ulcerated SMT   | Serous carcinoma | IV   | Surgery   | 0           | Chemotherapy | Alive at 1 year |
| 9             | 9         | 61  | L              | 2.4x3          | Ulcerated SMT   | Serous carcinoma | IV   | Surgery   | 72          | Surgery   | Alive at 5 months |
| 10            | 10        | 73  | L              | 6.5x6          | Gastric ulcer   | Serous carcinoma | IV   | Biopsy   | 42          | Chemotherapy | DOD at 7 months |
| 11            | 11        | 58  | L              | 3.5x3          | Ulcerated SMT   | Serous carcinoma | IIIB | EUS-FNA  | 36          | Chemotherapy | Alive at 3 months |
| 12            | 12        | 51  | L              | 4.5x2.9        | SMT             | Papillary serous carcinoma | ND   | EUS-FNA  | 25          | ND        | ND      |
| 13            | 13        | 43  | U              | 6x3            | Gastric ulcer   | Serous carcinoma | IIC  | Surgery   | 0           | Chemotherapy | Alive at 1 month |
| Present case  | 64        | U   | 1              | Ulcerated SMT  | Mucinous carcinoma | Biopsy  | IA   | Biopsy   | 3           | Chemotherapy | DOD at 4 months |

U: upper third of the stomach, M: middle third of the stomach, L: lower third of the stomach, EUS-FNA: endoscopic ultrasound-guided fine-needle aspiration, SMT: submucosal tumor, IPM: interval between the treatment of the primary tumor and the diagnosis of metastatic tumor in the stomach, ND: not described, DOD: dead of disease.
comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol 206: 242, e1-e5, 2012.

8. Ayhan A, Guitekin M, Celik NY, et al. Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol 196: 81.e1-e6, 2007.

9. Kim EY, Park CH, Jung ES, Song KY. Gastric metastasis from ovarian cancer presenting as a submucosal tumor: a case report. J Gastric Cancer 14: 138-141, 2014.

10. Yamao K, Kitano M, Kudo M, Maenishi O. EUS-FNA for metastases from ovarian carcinoma. Endoscopy 47: E596-E597, 2015.

11. Obediat F, Mismar A, Shomaf M, Yousef M, Fram K. Gastric perforation secondary to metastasis from ovarian cancer: Case report. Int J Surg 4: 541-543, 2013.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2018 The Japanese Society of Internal Medicine

Intern Med 57: 345-349, 2018